COX-2 inhibitors: a role for Alzheimer's disease?

Otten N
Record ID 31999009910
English, French
Authors' objectives:

To summarise the available evidence on the use of COX-2 inhibitors in the treatment or prevention of Alzheimer's disease.

Authors' recommendations: Several obstacles have stood in the way of obtaining definitive proof of benefit from NSAIDS: 1. A lack of a comprehensive list of risk factors for AD to assess protective effect. 2. The requirement for large size trials that may require many years to detect a decrease in the probability of developing AD. 3. A lack of agreement on suitable outcome endpoints. 4. No clear data to indicate the optimal timing of therapy. The long term adverse effects of NSAIDs have been one of the primary reasons for the emergence and testing of COX-2 inhibitors as a possible alternative to regular NSAIDs. Currently only animal and in vitro evidence exists. Clinical trials are required as well as long term experience with these drugs to assess their safety record.
Authors' methods: Overview
Project Status: Completed
Year Published: 1999
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Anti-Inflammatory Agents, Non-Steroidal
  • Costs and Cost Analysis
  • Alzheimer Disease
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.